An Epoxide-Mediated Deprotection Method for Acidic Amide Auxiliary

Qing-Lan Pei,[†] Guan-Da Che,[†] Ru-Yi Zhu,[‡] Jian He,[‡] and Jin-Quan Yu*[‡] †Asymchem Life Science (Tianjin) Co., Ltd., 71 7th Avenue, TEDA Tianjin 300457, P. R. China

Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037

Table of Contents

General Information	S1
Substrate Structures	S2
Experimental Section	
Substrate Preparation	S 3
Synthesis Intermediate Ester and Leaving Group	S 3
Amide Alcoholysis	S4
References	S16
¹ H and ¹³ C NMR Spectra	S16

General Information

Acids and 2,3,5,6-tetrafluoro-4-(trifluoromethyl)aniline were obtained from the commercial sources or synthesized following literature procedures, and used to prepare the corresponding amides. ¹H NMR was recorded on Varian Inova 500 instrument (500 MHz) or Varian Mercury Plus 400 instrument (400 MHz). Chemical shifts were quoted in parts per million (ppm) referenced to 0.0 ppm for tetramethylsilane. The following abbreviations (or combinations thereof) were used to explain multiplicities: s = singlet, d = doublet, t = triplet, q =quartet, m = multiplet, br = broad. Coupling constants, J, were reported in Hertz unit (Hz). ¹³C NMR spectra were recorded on Varian Inova 500 instrument (125 MHz) or Varian Mercury Plus 400 instrument (100 MHz), and were fully decoupled by broad band proton decoupling. ¹⁹F NMR spectra were recorded on Varian Mercury Plus 400 instrument (376 MHz), and were fully decoupled by broad band proton decoupling. Chemical shifts were reported in ppm referenced to either the center line of a triplet at 77.16 ppm of chloroform-d or the center line of a multiplet at 39.52 ppm of DMSO-d⁶. LC-MS was performed on an Agilent 1260 LC with an Agilent 6230 mass spectrometer (electrospray ionization, ESI) eluting with 0.05% trifluoroacetic acid in H₂O and 0.05% trifluoroacetic acid in CH₃CN. All starting materials and solvent were purchased from Alfa Aesar, Aldrich, Acros, TCI chemical companies or from the storehouse of Asychem Laboratories Inc. and used as received.

Substrate Structures

Experimental Section

Substrate Preparation

Substrates **1a-r** were prepared through traditional synthesis following literature procedure. Substrates **1s-ai** were prepared through C–H functionalization method following literature procedure. 1, 2, 3, 4, 5, 6

Synthesis Intermediate Ester and Leaving Group

The Procedure for the Synthesis of Intermediate Ester: An oven-dried 25 mL Schlenk tube was charged with substrate 1a (0.2 mmol, 86.9 mg), and then KOAc (0.2 mmol, 19.6 mg), 2-methoxyethyl ether (2 mL) and epoxide 2b (0.6 mmol, 98.5 mg) was successively added. After inertion (vacuum/nitrogen), the reaction mixture was stirred at 90 °C for 30 h. Upon completion, the reaction mixture was purified by column chromatography using hexane/EtOAc (10/1) as the eluent, and the product intermediate ester was obtained as colorless oil (103.0 mg, 86%).

1-(Benzyloxy)-3-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenylamino)propan-2-yl 2-(1,3-dioxoisoindolin-2-yl)propanoate (intermediate ester)

 1 H NMR (500 MHz, CDCl₃) δ 7.90 – 7.83 (m, 2H), 7.78 – 7.72 (m, 2H), 7.33 – 7.27 (m, 3H), 7.21 – 7.16 (m, 2H), 5.30 – 5.21 (m, 1H), 5.00 (q, J = 7.0 Hz, 2H), 4.92 (br, 1H), 4.46 (s, 2H), 3.90 – 3.82 (m, 1H), 3.64 – 3.58 (m, 1H), 3.57 – 3.48 (m, 2H), 3.58 – 3.48 (m, 1H), 1.65 (d, J = 7.5 Hz, 3H). 13 C NMR (125 MHz, CDCl₃) δ 169.41, 167.64, 137.44, 134.56, 131.81, 128.60, 128.01, 127.62, 123.74, 73.57, 73.29, 68.98, 47.48, 46.05, 15.77. HRMS (ESI-TOF) Calcd for $C_{28}H_{22}F_7N_2O_5$ [M+H] $^+$: 599.1411, found: 599.1413.

The Procedure for the Synthesis of Leaving Group: An oven-dried 25 mL Schlenk tube was charged with intermediate ester (0.2 mmol, 119.7 mg), and then KOAc (0.2 mmol, 19.6 mg) and EtOH (2 mL) was successively added. After inertion (vacuum/nitrogen), the reaction mixture was stirred at 90 °C for 15 h. Upon completion, the reaction mixture was purified by column chromatography using hexane/EtOAc (10/1) as the eluent, and the product leaving group was obtained as colorless oil.

1-(Benzyloxy)-3-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenylamino)propan-2-ol (leaving group)


¹H NMR (500 MHz, CDCl₃) δ 7.41 – 7.28 (m, 5H), 4.73 (s, 1H), 4.61 – 4.52 (m, 1H), 4.05 – 3.97 (m, 1H), 3.70 – 3.62 (m, 1H), 3.61 – 3.57 (m, 1H), 3.52 – 3.42 (m, 2H), 2.63 (br, 1H). HRMS (ESI-TOF) Calcd for $C_{17}H_{15}F_7NO_2$ [M+H]⁺: 398.0986, found: 398.0986. ¹³C NMR (125 MHz, CDCl₃) δ 137.47, 128.72, 128.23, 127.98, 73.81, 71.87, 69.52, 47.73 (t, *J* = 3.5 Hz). HRMS (ESI-TOF) Calcd for $C_{17}H_{15}FNO_2$ [M+H]⁺: 398.0986, found: 398.0988.


Amide Alcoholysis

General Procedures for the Amide Alcoholysis: An oven-dried 25 mL Schlenk tube was charged with substrate 1 (0.2 mmol), and then KOAc (0.2 mmol, 19.6 mg), EtOH (2 mL, the water content of the solvent was below 0.01wt %) and epoxide 2a (0.6 mmol, 52.9 mg) was successively added. After inertion (vacuum/nitrogen), the reaction mixture was stirred at 90 °C for 35 h. Upon completion, the solvent was removed under reduced pressure. The residue was purified by column chromatography using hexane/EtOAc as the eluent (Rf value of all products is between 0.3 and 0.5 with specific eluent notified).

Ethyl 2-(1,3-dioxoisoindolin-2-yl)propanoate (3a)

Substrate **1a** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (15/1) as the eluent, **3a** was obtained as a colorless oil (45.8 mg, 93%). 1 NMR (500 MHz, CDCl₃) δ 7.92 – 7.79 (m, 2H), 7.77 – 7.60 (m, 2H), 4.95 (q, J = 7.5 Hz, 1H), 4.19 (td, J = 7.0, 3.5 Hz, 2H), 1.69 (d, J = 7.5 Hz, 3H), 1.22 (t, J = 7.0 Hz, 3H). 13 C NMR (125 MHz, CDCl₃) δ 169.75, 167.47, 134.20, 131.99, 123.49, 61.90, 47.66, 15.28, 14.12. HRMS (ESI-TOF) Calcd for $C_{13}H_{14}NO_{4}$ [M+H] $^{+}$: 248.0917, found: 248.0919.






Instrument:HPLC-019
Sequence:120265-1319
Data File:chrom/(chromeleon-011/XVault/HPLC-019/3607/120265-1319.seq/684.smp/UV_VIS_1.channel/UV_VIS_1.ch

Page 1 of 1

	Chromatogram and Results			CASYMCHEM
Injection Details				Ť
Injection Name:	CD120265-01-PQL-9019-13		Run Time (min):	19.99
Vial Number:	Vial:85		Injection Volume:	5.00
Creation operator:	zhangyan		User Name:	zhangyan
Instrument Method:	LC-052516-01-120265		Comment:	
Processing Method:	New Processing Method		Dilution Factor:	1.0000
Injection Date/Time:	04/Jun/16 17:20		Sample Weight:	1.0000



Methyl 2-(1,3-dioxoisoindolin-2-yl)propanoate (3a1)

Substrate **1a** was alcoholized following the general alcoholysis procedure. MeOH was used as the solvent. After purification by column chromatography using hexane/EtOAc (15/1) as the eluent, **3a1** was obtained as a colorless oil (42.5 mg, 91%). 1 NMR (500 MHz, CDCl₃) δ 7.88 – 7.81 (m, 2H), 7.75 – 7.69 (m, 2H), 4.96 (q, J = 7.5 Hz, 1H), 3.72 (s, 3H), 1.68 (d, J = 7.5 Hz, 3H). 13 C NMR (125 MHz, CDCl₃) δ 170.24, 167.42, 134.23, 131.94, 123.54, 52.83, 47.42, 15.33. HRMS (ESI-TOF) Calcd for $C_{12}H_{12}NO_4$ [M+H] $^{+}$: 234.0761, found: 234.0761.

Isopropyl 2-(1,3-dioxoisoindolin-2-yl)propanoate (3a2)

Substrate **1a** was alcoholized following the general alcoholysis procedure. *i*-PrOH was used as the solvent. After purification by column chromatography using hexane/EtOAc (15/1) as the eluent, **3a2** was obtained as a colorless oil (49.5 mg, 95%). 1 NMR (500 MHz, CDCl₃) δ 7.90 – 7.80 (m, 2H), 7.75 – 7.69 (m, 2H), 5.11 – 4.99 (m, 1H), 4.91 (q, J = 7.5 Hz, 1H), 1.66 (d, J = 7.5 Hz, 3H), 1.20 (dd, J = 20.0, 6.5 Hz, 6H). 13 C NMR (125 MHz, CDCl₃) δ 169.22, 167.51, 134.19, 132.01, 123.49, 47.82, 21.76, 21.68, 15.33. HRMS (ESI-TOF) Calcd for $C_{14}H_{16}NO_4$ [M+H] $^{+}$: 262.1074, found: 262.1081.

Isobutyl 2-(1,3-dioxoisoindolin-2-yl)propanoate (3a3)

Substrate **1a** was alcoholized following the general alcoholysis procedure. *i*-BuOH was used as the solvent. After purification by column chromatography using hexane/EtOAc (20/1) as the eluent, **3a3** was obtained as a colorless oil (50.7 mg, 92%). 1 NMR (500 MHz, CDCl₃) δ 7.87 – 7.79 (m, 2H), 7.75 – 7.68 (m, 2H), 4.96 (q, J = 7.5 Hz, 1H), 3.96 – 3.86 (m, 2H), 1.93 – 1.79 (m, 1H), 1.69 (d, J = 7.5 Hz, 3H), 0.83 (dd, J = 7.0, 1.0 Hz, 6H). 13 C NMR (125 MHz, CDCl₃) δ 169.74, 167.50, 134.22, 131.96, 123.49, 71.80, 47.64, 27.66, 18.97, 18.95, 15.30. HRMS (ESI-TOF) Calcd for $C_{15}H_{18}NO_4$ [M+H] $^{+}$: 276.1230, found: 276.1232.

Isopentyl 2-(1,3-dioxoisoindolin-2-yl)propanoate (3a4)

Substrate **1a** was alcoholized following the general alcoholysis procedure. *i*-AmylOH was used as the solvent. After purification by column chromatography using hexane/EtOAc (20/1) as the eluent, **3a4** was obtained as a colorless oil (50.2 mg, 87%). 1 NMR (500 MHz, CDCl₃) δ 7.88 – 7.81 (m, 2H), 7.76 – 7.70 (m, 2H), 5.00 – 4.91 (m, 1H), 4.16 (t, J = 7.0 Hz, 2H), 1.68

(d, J = 8.0 Hz, 3H), 1.64 - 1.52 (m, 1H), 1.52 - 1.37 (m, 2H), 0.87 - 0.72 (m, 6H). 13 C NMR (125 MHz, CDCl₃) δ 169.82, 167.55, 134.23, 132.03, 123.54, 64.63, 47.70, 37.16, 25.13, 22.50, 22.41, 15.35. HRMS (ESI-TOF) Calcd for $C_{16}H_{20}NO_4$ [M+H] $^+$: 290.1387, found: 290.1387.

Ethyl 3-phenylpropanoate (3b)

Substrate **1k** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (30/1) as the eluent, **3b** was obtained as a colorless oil (34.5 mg, 97%). 1 H NMR (500 MHz, CDCl₃) δ 7.32 – 7.26 (m, 2H), 7.24 – 7.17 (m, 3H), 4.13 (q, J = 7.0 Hz, 2H), 2.96 (t, J = 8.0 Hz, 2H), 2.63 (t, J = 8.0 Hz, 2H), 1.24 (t, J = 7.0 Hz, 3H). 13 C NMR (125 MHz, CDCl₃) δ 172.98, 140.68, 128.56, 128.39, 126.31, 60.49, 36.05, 31.09, 14.30. HRMS (ESI-TOF) Calcd for $C_{11}H_{15}O_{2}$ [M+H]⁺: 179.1067, found: 179.1065.

Ethyl 2,2-dimethyl-3-phenylpropanoate (3c)

Substrate **11** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (20/1) as the eluent, **3c** was obtained as a colorless oil (38.8 mg, 94%). 1 H NMR (500 MHz, CDCl₃) δ 7.30 – 7.27 (m, 2H), 7.25 – 7.20 (m, 1H), 7.13 (d, J = 7.0 Hz, 2H), 4.13 (q, J = 7.0 Hz, 2H), 2.87 (s, 2H), 1.25 (t, J = 7.0 Hz, 3H), 1.19 (s, 6H). 13 C NMR (125 MHz, CDCl₃) δ 177.62, 138.10, 130.30, 128.06, 126.52, 60.52, 46.41, 43.61, 25.09, 14.31. HRMS (ESI-TOF) Calcd for $C_{13}H_{19}O_{2}$ [M+H] $^{+}$: 207.1380, found: 207.1376.

Ethyl 2-(1,3-dioxoisoindolin-2-yl)-2-methylpropanoate (3d)

Substrate **1m** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (15/1) as the eluent, **3d** was obtained as a colorless oil (47.1 mg, 90%). 1 NMR (500 MHz, CDCl₃) δ 7.82 – 7.76 (m, 2H), 7.73 – 7.65 (m, 2H), 4.20 (q, J = 7.0 Hz, 2H), 1.81 (s, 6H), 1.22 (t, J = 7.0 Hz, 3H). 13 C NMR (125 MHz, CDCl₃) δ 172.97, 168.40, 134.12, 131.96, 123.19, 61.72, 60.46, 29.79, 24.51, 14.14. HRMS (ESI-TOF) Calcd for $C_{14}H_{16}NO_{4}$ [M+H] $^{+}$: 262.1074, found: 262.1073.

Ethyl 1-(1,3-dioxoisoindolin-2-yl)cyclopropanecarboxylate (3e)

Substrate **1n** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (15/1) as the eluent, **3e** was obtained as a colorless oil (47.6 mg, 92%). 1 H NMR (500 MHz, CDCl₃) δ 7.91 – 7.82 (m, 2H), 7.79 – 7.68 (m, 2H), 4.11 (dd, J = 14.0, 7.0 Hz, 2H), 1.83 (dd, J = 8.5, 5.0 Hz, 2H), 1.44 (dd, J = 8.5, 5.0 Hz, 2H), 1.16 (t, J = 7.0 Hz, 3H). 13 C NMR (125 MHz, CDCl₃) δ 170.59, 168.16, 134.34, 131.76, 123.57, 61.93, 31.75, 16.27, 14.17. HRMS (ESI-TOF) Calcd for $C_{14}H_{14}NO_{4}$ [M+H] $^{+}$: 260.0917, found: 260.0918.

Ethyl 1-benzoylpyrrolidine-2-carboxylate (3f)

Substrate **10** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (15/1) as the eluent, **3f** was obtained as a colorless oil (43.9 mg, 89%). 1 H NMR (500 MHz, CDCl₃) δ 7.55 (d, J = 6.5 Hz, 2H), 7.43 – 7.35 (m, 3H), 4.69 – 4.59 (m, 1H), 4.22 (q, J = 7.0 Hz, 2H), 3.64 (dt, J = 14.0, 7.0 Hz, 1H), 3.56 – 3.47 (m, 1H), 2.31 (dd, J = 14.0, 7.0 Hz, 1H), 2.04 – 1.97 (m, 2H), 1.92 – 1.82 (m, 1H), 1.29 (t, J = 7.0 Hz, 3H). 13 C NMR (125 MHz, CDCl₃) δ 172.36, 169.73, 136.38, 130.23, 128.33, 127.33, 61.22, 59.37, 50.03, 29.51, 25.47, 14.30. HRMS (ESI-TOF) Calcd for $C_{14}H_{18}NO_{3}$ [M+H] $^{+}$: 248.1281, found: 248.1286.

Ethyl 1-benzoylpiperidine-4-carboxylate (3g)⁷

Substrate **1p** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (5/1) as the eluent, **3g** was obtained as a colorless oil (47.6 mg, 91%). 1 H NMR (500 MHz, CDCl₃) δ 7.47 – 7.33 (m, 5H), 4.66 – 4.37 (m, 1H), 4.15 (q, J = 7.0 Hz, 2H), 3.84 – 3.55 (m, 1H), 3.16 – 3.93 (m, 2H), 2.61 – 2.52 (m, 1H), 2.11 – 1.70 (m, 4H), 1.25 (d, J = 7.0 Hz, 3H). 13 C NMR (125 MHz, CDCl₃) δ 174.29, 170.57, 136.13, 129.74, 128.61, 126.94, 60.79, 47.12, 41.64, 41.21, 29.83, 14.32. Calcd for $C_{15}H_{20}NO_3$ [M+H] $^{+}$: 262.1438, found: 262.1420.

Ethyl 2-methyl-3-phenylacrylate (3h)

Substrate **1q** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (20/1) as the eluent, **3h** was obtained as a colorless oil (34.7 mg, 91%). 1 H NMR (500 MHz, CDCl₃) δ 7.70 (s, 1H), 7.43 – 7.36 (m, 4H), 7.35 – 7.29 (m, 1H), 4.28 (q, J = 7.0 Hz, 2H), 2.13 (s, 3H), 1.36 (t, J = 7.0 Hz, 3H). 13 C NMR (125 MHz, CDCl₃) δ 168.81, 138.76, 136.09, 129.75, 128.76, 128.47, 128.35, 61.00, 14.46, 14.18. HRMS (ESI-TOF) Calcd for $C_{12}H_{15}O_{2}$ [M+H]⁺: 191.1067, found: 191.1065.

Ethyl benzoate (3i)

Substrate **1r** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (30/1) as the eluent, **3i** was obtained as a colorless oil (18.5 mg, 62%). 1 H NMR (500 MHz, CDCl₃) δ 8.11 – 8.01 (m, 2H), 7.59 – 7.52 (m, 1H), 7.48 – 7.40 (m, 2H), 4.38 (q, J = 7.0 Hz, 2H), 1.40 (t, J = 7.0 Hz, 3H). 13 C NMR (125 MHz, CDCl₃) δ 166.75, 132.91, 130.61, 129.64, 128.42, 61.07, 14.46. HRMS (ESI-TOF) Calcd for $C_{9}H_{11}O_{2}$ [M+H]⁺: 151.0754, found: 151.0739.

Ethyl 4-(3-ethoxy-2-(4-isobutylphenyl)-3-oxopropyl)benzoate (3j)

Substrate **1s** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (25/1) as the eluent, **3j** was obtained as a colorless oil (72.4 mg, 95%). 1 H NMR (400 MHz, CDCl₃) δ 7.91 (d, J = 8.0 Hz, 2H), 7.21 – 7.17 (m, 4H), 7.08 (d, J = 8.0 Hz, 2H), 4.35 (q, J = 8.0 Hz, 2H), 4.15 – 3.96 (m, 2H), 3.83 – 3.76 (m, 1H), 3.46 – 3.41 (m, 1H), 3.08 – 3.03 (m, 1H), 2.44 (d, J = 8.0 Hz, 2H), 1.89 – 1.79 (m, 1H), 1.38 (t, J = 8.0 Hz, 3H), 1.12 (t, J = 8.0 Hz, 3H), 0.89 (d, J = 8.0 Hz, 6H). 13 C NMR (125 MHz, CDCl₃) δ 173.30, 166.65, 144.65, 141.00, 135.66, 129.63, 129.47, 129.08, 128.70, 127.65, 60.91, 53.05, 45.11, 39.95, 30.26, 22.44, 14.42, 14.14. HRMS (ESI-TOF) Calcd for $C_{24}H_{31}O_4$ [M+H] $^+$: 383.2217, found: 383.2216.

Diethyl 4,4'-(3-ethoxy-2-(4-isobutylphenyl)-3-oxopropane-1,1-diyl) dibenzoate (3k)

Substrate **1t** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (25/1) as the eluent, **3k** was obtained as a colorless oil (101.5 mg, 96%). ¹H NMR (500 MHz, CDCl₃) δ 7.99 (d, J = 8.0 Hz, 2H), 7.73 (d, J = 8.0 Hz, 2H), 7.48 (d, J = 8.0 Hz, 2H), 7.15 (d, J = 8.0 Hz, 2H), 7.06 (d, J = 8.0 Hz, 2H), 6.94 (d, J = 8.0 Hz, 2H), 4.79 (d, J = 12.0 Hz, 1H), 4.40 – 4.33 (m, 3H), 4.27 (q, J = 7.0 Hz, 2H), 4.02 – 3.96 (m, 1H), 3.94 – 3.88 (m, 1H), 2.35 (d, J = 7.0 Hz, 2H), 1.79 – 1.73 (m, 1H), 1.37 (t, J = 7.0 Hz, 3H), 1.31 (t, J = 7.0 Hz, 3H), 1.01 (t, J = 7.0 Hz, 3H), 0.82 – 0.80 (m, 6H). ¹³C NMR (126 MHz, CDCl₃) δ 172.47, 166.47, 166.43, 147.42, 146.29, 141.21, 133.58, 130.12, 129.67, 129.42, 128.49, 128.28, 127.95, 61.07, 60.95, 56.16, 55.00, 45.07, 30.20, 22.41, 22.38, 14.47, 14.40, 14.05. HRMS (ESI-TOF) Calcd for $C_{33}H_{39}O_6$ [M+H]⁺: 531.2741, found: 531.2739.

Ethyl 2-((2-fluoropyridin-4-yl)methyl)butanoate (3l)

Substrate **1u** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (15/1) as the eluent, **3l** was obtained as a colorless oil (42.4 mg, 94%). 1 H NMR (500 MHz, CDCl₃) δ 8.09 (d, J = 5.0 Hz, 1H), 6.99 (d, J = 5.0 Hz, 1H), 6.74 (s, 1H), 4.15 – 4.01 (m, 2H), 2.96 (dd, J = 14.0, 9.5 Hz, 1H), 2.77 (dd, J = 14.0, 6.0 Hz, 1H), 2.65 – 2.55 (m, 1H), 1.72 – 1.65 (m, 1H), 1.63 – 1.53 (m, 1H), 1.16 (t, J = 7.0 Hz, 3H), 0.94 (t, J = 7.5 Hz, 3H). 13 C NMR (125 MHz, CDCl₃) δ 174.66, 164.15 (d, J = 237.5 Hz), 154.76 (d, J = 7.5 Hz), 147.57 (d, J = 15.0 Hz), 122.07 (d, J = 3.8 Hz), 109.75 (d, J = 36.3 Hz), 60.65, 48.01, 37.14 (d, J = 2.5 Hz), 25.63, 14.33, 11.66. 19 F NMR (376 MHz, CDCl₃) δ -69.29 (S). HRMS (ESI-TOF) Calcd for $C_{12}H_{17}$ FNO₂ [M+H]⁺: 226.1238, found: 226.1238.

Ehyl 2-(5-isobutylbiphenyl-2-yl)propanoate (3m)

Substrate **1v** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (50/1) as the eluent, **3m** was obtained as a colorless oil (59.8 mg, 96%). ¹H NMR (500 MHz, CDCl₃) δ 7.47 – 7.40 (m, 2H), 7.36 (m, 4H), 7.15 (d, J = 8.0 Hz, 1H), 7.04 (s, 1H), 4.17 – 4.05 (m, 2H), 3.87 (q, J = 7.0 Hz, 1H), 2.49 (d, J = 7.0 Hz, 2H), 1.94 – 1.86 (m, 1H), 1.37 (d, J = 7.0 Hz, 3H), 1.20 (t, J = 7.0 Hz, 3H), 0.94 (d, J = 6.5 Hz, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 175.21, 141.65, 141.51, 140.05, 136.04, 130.96, 129.59, 128.68, 128.16, 127.04, 126.62, 60.63, 45.12, 41.02, 30.23, 22.57, 22.55, 19.39, 14.20. HRMS (ESI-TOF) Calcd for $C_{21}H_{27}O_2$ [M+H]⁺: 311.2006, found: 311.2006.

Ethyl 2-(1,3-dioxoisoindolin-2-yl)-3-p-tolylpropanoate (3n)

Substrate **1w** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (15/1) as the eluent, **3n** was obtained as a colorless oil (63.1 mg, 93%). ¹H NMR (500 MHz, CDCl₃) δ 7.82 – 7.74 (m, 2H), 7.71 – 7.63 (m, 2H), 7.04 (d, J = 8.0 Hz, 2H), 6.98 (d, J = 8.0 Hz, 2H), 5.15 – 5.08 (m, 1H), 4.27 – 4.20 (m, 2H), 3.58 – 3.46 (m, 2H), 2.22 (s, 3H), 1.25 (t, J = 7.0 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 169.02, 167.65, 136.40, 134.15, 133.79, 131.77, 129.35, 128.80, 123.56, 62.12, 53.68, 34.33, 21.13, 14.25. HRMS (ESI-TOF) Calcd for $C_{20}H_{20}NO_4$ [M+H]⁺: 338.1387, found: 338.1388.

Ethyl 2-(1,3-dioxoisoindolin-2-yl)-3-phenyl-3-p-tolylpropanoate (30)

Substrate **1x** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (20/1) as the eluent, **3o** was obtained as a colorless oil (62.2 mg, 75%). 1 H NMR (500 MHz, CDCl₃) δ 7.83 – 7.69 (m, 2H), 7.69 – 7.62 (m, 2H), 7.50 (d, J = 7.5 Hz, 1H), 7.41 (d, J = 7.5 Hz, 1H), 7.33 (t, J = 7.5 Hz, 1H), 7.27 (d, J = 9.0 Hz, 1H), 7.22 (t, J = 7.5 Hz, 0.5H), 7.17 (t, J = 7.0 Hz, 2H), 7.11 (t, J = 7.5 Hz, 1H), 6.99 (t, J = 7.5 Hz, 0.5H), 6.93 (d, J = 7.5 Hz, 1H), 5.78 – 5.71 (m, 1H), 5.33 – 5.23 (m, 1H), 4.13 – 3.98 (m, 2H), 2.32 (s, 1.5H), 2.13 (s, 1.5H), 1.06 – 0.98 (m, 3H). 13 C NMR (125 MHz, CDCl₃) δ 168.43, 168.37, 167.49, 167.44, 142.03, 140.84, 138.75, 137.61, 136.46, 136.44, 134.11, 131.52, 131.45, 129.47, 129.32, 128.73, 128.57, 127.98, 127.83, 127.81, 127.70, 126.85, 123.50, 123.45, 77.41, 77.16, 76.91, 61.75, 61.71, 55.40, 55.26, 50.33, 50.29, 29.81, 21.14, 20.99, 13.83. HRMS (ESI-TOF) Calcd for $C_{26}H_{24}NO_4$ [M+H] $^+$: 414.1700, found: 414.1703.

Methyl 4-(2-(methoxycarbonyl)cyclopropyl)benzoate (3p)

Substrate **1y** was alcoholized following the general alcoholysis procedure. MeOH was used as the solvent. After purification by column chromatography using hexane/EtOAc (10/1) as the eluent, **3p** was obtained as a colorless oil (43.2 mg, 92%). ¹NMR (400 MHz, CDCl₃) δ 7.94 (d, J = 8.0 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 3.89 (s, 3H), 3.43 (s, 3H), 2.60 (q, J = 8.0 Hz, 1H), 2.18 – 2.13 (m, 1H), 1.77 – 1.72 (m, 1H), 1.43 – 1.37 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 171.20, 167.14, 142.09, 129.36, 128.66, 52.15, 51.71, 25.60, 22.16, 11.75. HRMS (ESI-TOF) Calcd for C₁₃H₁₅O₄ [M+H]⁺: 235.0965, found: 235.0966.

Ethyl 4-(2-(1,3-dioxoisoindolin-2-yl)-2-(ethoxycarbonyl)cyclopropyl) benzoate (3q)

Substrate **1z** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (10/1) as the eluent, **3q** was obtained as a colorless oil (73.9 mg, 91%). ¹H NMR (500 MHz, CDCl₃) δ 8.02 (d, J = 8.0 Hz, 2H), 7.92 – 7.91 (m, 2H), 7.79 – 7.77 (m, 2H), 7.68 (d, J = 8.0 Hz, 2H), 4.38 (q, J = 7.0 Hz, 2H), 3.84 – 3.76 (m, 2H), 3.17 (t, J = 9.5 Hz, 1H), 2.51 (dd, J = 9.0, 6.5 Hz, 1H), 1.94 (dd, J = 9.0, 6.5 Hz, 1H), 1.40 (t, J = 7.0 Hz, 3H), 0.78 (t, J = 7.0 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 168.22, 167.65, 166.66, 140.20, 134.56, 131.87, 129.91, 129.46, 123.76, 61.74, 61.07, 38.21, 33.48, 19.24, 14.50, 13.84. HRMS (ESI-TOF) Calcd for $C_{23}H_{22}NO_6$ [M+H]⁺: 408.1442, found: 408.1442.

Methyl 4-(2-(methoxycarbonyl)cyclobutyl)benzoate (3r)

Substrate **1aa** was alcoholized following the general alcoholysis procedure. MeOH was used as the solvent. After purification by column chromatography using hexane/EtOAc (10/1) as the eluent, **3r** was obtained as a colorless oil (46.3 mg, 93%). 1 H NMR (400 MHz, CDCl₃) δ 7.98 (d, J = 8.0 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 3.91 (s, 3H), 3.88 – 3.81 (m, 1H), 3.71 (s, 3H), 3.22 (q, J = 8.0 Hz, 1H), 2.38 – 2.31 (m, 2H), 2.29 – 2.12 (m, 2H). 13 C NMR (125 MHz, CDCl₃) δ 174.66, 167.13, 148.93, 129.86, 128.39, 126.50, 52.16, 51.94, 45.07, 43.10, 25.33, 21.90. HRMS (ESI-TOF) Calcd for $C_{14}H_{17}O_{4}[M+H]^{+}$: 249.1121, found: 249.1128

Dimethyl 4,4'-(2-(methoxycarbonyl)cyclobutane-1,3-diyl)dibenzoate (3s)

Substrate **1ab** was alcoholized following the general alcoholysis procedure. MeOH was used as the solvent. After purification by column chromatography using hexane/EtOAc (10/1) as the eluent, **3s** was obtained as a colorless oil (72.4 mg, 95%). 1 H NMR (400 MHz, CDCl₃) δ 8.00 (d, J = 8.0 Hz, 4H), 7.34 (d, J = 8.0 Hz, 4H), 3.91 (s, 6H), 3.84 (q, J = 8.0 Hz, 2H), 3.75 (s, 3H), 3.32 – 3.28 (m, 1H), 2.87 – 2.81 (m, 1H), 2.34 – 2.26 (m, 1H). 13 C NMR (125 MHz, CDCl₃) δ 173.61, 167.04, 147.96, 130.01, 128.73, 126.67, 52.26, 52.23, 51.98, 39.53, 32.49, 29.85. HRMS (ESI-TOF) Calcd for $C_{22}H_{23}O_{6}$ [M+H]⁺: 383.1489, found: 383.1458.

Ethyl 4-(2-(ethoxycarbonyl)cyclopentyl)benzoate (3t)

Substrate **1ac** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (10/1) as the eluent, **3t** was obtained as a colorless oil (53.6 mg, 92%). ¹H NMR (500 MHz, CDCl₃) δ 7.96 (t, J = 8.0 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 4.35 (q, J = 7.0 Hz, 2H), 4.05 (q, J = 7.0 Hz, 2H), 3.37 (q, J = 9.0 Hz, 1H), 2.81 (q, J = 9.0 Hz, 1H), 2.24 – 2.10 (m, 2H), 2.02 – 1.93 (m, 1H), 1.91 – 1.79 (m, 2H), 1.79 – 1.69 (m, 1H), 1.37 (t, J = 7.0 Hz, 3H), 1.14 (t, J = 7.0 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 175.54, 166.67, 149.47, 129.83, 128.74, 127.34, 60.90, 60.50, 52.18, 49.86, 35.08, 30.84, 25.16, 14.47, 14.31. HRMS (ESI-TOF) Calcd for $C_{17}H_{23}O_4$ [M+H]⁺: 291.1591, found: 291.1591.

cis-Ethyl 4-(2-(ethoxycarbonyl)cyclohexyl)benzoate (cis-3u)

Substrate **1ad** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (10/1) as the eluent, *cis-3u* was obtained as colorless oil (50.5 mg, 83%) and *trans-3u* was obtained as colorless oil (4.0 mg, 6%). The configuration of *cis-3n* was assigned as cis- based on the 1 H spectrum data of *cis-3u* match those of the reported compound cis- N-(2,3,5,6-Tetrafluoro-4-(trifluoromethyl)phenyl)-2-p-tolylcyclohexanecarboxamide. H NMR (500 MHz, CDCl₃) δ 7.94 (d, J = 8.0 Hz, 2H), 7.26 (d, J = 8.0 Hz, 2H), 4.35 (q, J = 7.0 Hz, 2H), 3.90 – 3.80 (m, 2H), 2.89 – 2.76 (m, 1H), 2.63 – 2.53 (m, 1H), 2.08 – 1.99 (m, 1H), 1.92 – 1.78 (m, 3H), 1.62 – 1.56 (m, 1H), 1.50 – 1.42 (m, 2H), 1.42 – 1.34 (m, 4H), 0.94 (t, J = 7.0 Hz, 3H). 13 C NMR (125 MHz, CDCl₃) δ 174.95, 166.72, 150.21, 129.75, 128.74, 127.49, 60.90, 60.09, 49.97, 46.82, 34.18, 30.17, 26.19, 25.42, 14.47, 14.10. HRMS (ESI-TOF) Calcd for $C_{18}H_{25}O_4$ [M+H]⁺: 305.1747, found: 305.1749.

trans-Ethyl 4-(2-(ethoxycarbonyl)cyclohexyl)benzoate (*trans*-3u): 1 H NMR (500 MHz, CDCl₃) δ 7.95 (d, J = 8.0 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 4.40 – 4.31 (m, 2H), 3.93 – 3.80 (m, 2H), 3.02 – 2.90 (m, 2H), 2.40 – 2.32 (m, 1H), 2.11 – 2.05 (m, 1H), 1.94 – 1.88 (m, 1H), 1.84 – 1.71 (m, 3H), 1.62 – 1.53 (m, 2H), 1.38 (t, J = 7.0 Hz, 3H), 0.98 (t, J = 7.0 Hz, 3H). HRMS (ESI-TOF) Calcd for $C_{18}H_{25}O_{4}$ [M+H]⁺: 305.1747, found: 305.1747.

Ethyl 1-benzoyl-4-(4-methoxyphenyl)piperidine-3-carboxylate (3v)

Substrate **1ae** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (20/1) as the eluent, **3v** was obtained as a colorless oil (69.2 mg, 94%). 1 H NMR (500 MHz, CDCl₃) δ 7.47 – 7.38 (m, 5H), 7.11 (d, J = 8.5 Hz, 2H), 6.83 (d, J = 8.5 Hz, 2H), 5.08 – 4.76 (m, 1H), 4.00 – 3.78 (m, 3H), 3.77 (s, 3H), 3.31 – 2.56 (m, 4H), 1.90 – 1.56 (m, 2H), 1.00 – 0.77 (m, 3H). 13 C NMR (125 MHz, CDCl₃) δ 170.60, 158.65, 135.74, 134.33, 129.97, 128.67, 128.38, 127.09, 114.01, 60.53, 55.35, 29.78, 14.00. HRMS (ESI-TOF) Calcd for $C_{22}H_{26}NO_3$ [M+H] $^{+}$: 368.1856, found: 368.1838.

Ethyl 1-benzoyl-3-(4-methoxyphenyl)piperidine-4-carboxylate (**3w**) Substrate **1af** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (20/1) as the eluent, **3w** was obtained as a colorless oil (66.1 mg, 90%). ¹H NMR (500 MHz, CDCl₃) δ 7.45 – 7.32 (m, 5H), 7.20 – 6.95 (m, 2H), 6.93 – 6.70 (m, 2H), 4.99 – 4.68 (m, 1H), 3.93 (dd, J = 14.0, 7.0 Hz, 2H), 3.77 (s, 3H), 3.17 – 2.68 (m, 4H), 2.19 – 1.53 (m, 4H), 1.01 (t, J = 7.0 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 173.65, 170.56, 158.86, 129.89, 128.68, 127.00, 114.11, 60.56, 55.48, 55.36, 48.78, 29.85, 14.13. HRMS (ESI-TOF) Calcd for $C_{22}H_{26}NO_3$ [M+H]⁺: 368.1856, found: 368.1834.

(E)-ethyl 2-methyl-3-phenylbut-2-enoate (3x)⁸

Substrate **1ag** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (30/1) as the eluent, **3x** was obtained as a colorless oil (38.7 mg, 95%). 1 H NMR (500 MHz, CDCl₃) δ 7.42 – 7.35 (m, 2H), 7.32 – 7.28 (m, 1H), 7.17 (d, J = 7.0 Hz, 2H), 4.34 – 4.24 (m, 2H), 2.28 (d, J = 1.5 Hz, 3H), 1.78 (d, J = 1.5 Hz, 3H), 1.38 (t, J = 7.0 Hz, 3H). The 1 H NMR spectral data matches that of previously reported: *Org. Lett.* **2002**, *4*, 189-191. HRMS (ESI-TOF) Calcd for $C_{13}H_{17}O_{2}$ [M+H] $^{+}$: 205.1223, found: 205.1223.

Ethyl 2-(1,3-dioxoisoindolin-2-yl)-5-(triisopropylsilyl)pent-4-ynoate (3y)

Substrate **1ah** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (20/1) as the eluent, **3y** was obtained as a colorless oil (72.5 mg, 85%). 1 H NMR (500 MHz, CDCl₃) δ 7.88 – 7.81 (m, 2H), 7.76 – 7.69 (m, 2H), 5.08 (dd, J = 12.0, 5.0 Hz, 1H), 4.29 – 4.15 (m, 2H), 3.36 (dd, J = 17.5, 12.0 Hz, 1H), 3.11 (dd, J = 17.5, 5.0 Hz, 1H), 1.23 (t, J = 7.0 Hz, 3H), 0.88 – 0.76 (m, 21H). 13 C NMR (125 MHz, CDCl₃) δ 168.05, 167.31, 134.21, 132.02, 123.59, 102.79, 83.66, 62.28, 50.91, 20.86, 18.43, 18.42, 14.19, 11.11. HRMS (ESI-TOF) Calcd for $C_{24}H_{34}NO_4Si$ [M+H]*: 428.2252, found: 428.2250.

Ethyl 2-(4-isobutyl-2-((triisopropylsilyl)ethynyl)phenyl)propanoate (3z)

Substrate **1ai** was alcoholized following the general alcoholysis procedure. After purification by column chromatography using hexane/EtOAc (50/1) as the eluent, **3z** was obtained as a colorless oil (77.5 mg, 93%). ¹H NMR (500 MHz, CDCl₃) δ 7.27 – 7.25 (m, 1H), 7.21 (d, J =

8.0 Hz, 1H), 7.11 – 7.04 (m, 1H), 4.37 (q, J = 7.0 Hz, 1H), 4.21 – 4.03 (m, 2H), 2.41 (d, J = 7.0 Hz, 2H), 1.85 (dp, J = 14.0, 7.0 Hz, 1H), 1.47 (d, J = 7.0 Hz, 3H), 1.20 (t, J = 7.0 Hz, 3H), 1.14 (s, 18H), 0.90 (d, J = 7.0 Hz, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 174.82, 140.59, 140.27, 133.38, 129.90, 126.21, 122.75, 105.43, 94.54, 60.74, 44.90, 42.85, 30.18, 22.53, 22.52, 18.83, 18.66, 14.25, 11.53. HRMS (ESI-TOF) Calcd for $C_{26}H_{43}O_2Si$ [M+H]⁺: 415.3027, found: 415.3024.

Procedure for scale up synthesis of 3m

An oven-dried 250 mL Schlenk tube was charged with substrate **1v** (2.032 mmol, 1.011g), and then KOAc (2.032 mmol, 199 mg), EtOH (20 mL, the water content of the solvent was 0.01wt %) and epoxide **2a** (6.096 mmol, 537 mg) was successively added. After inertion (vacuum/nitrogen), the reaction mixture was stirred at 90 °C for 35 h. Upon completion, the solvent was removed under reduced pressure. The residue was purified by column chromatography using hexane/EtOAc(50/1) as the eluent, **3m** was obtained as a colorless oil (600 mg, 95%).

Procedure for one-pot synthesis of 3m³

An oven-dried 250 mL Schlenk tube was charged with amide substrate (2.374 mmol, 1.000 g), $Pd(OAc)_2$ (0.237 mmol, 53 mg), 7-(tert-butyl)-2,5-dimethyl-3,4-dihydro- 2H-pyrano[2,3-b]-quinoline (0.475 mmol, 128 mg), AgF (7.122 mmol, 903 mg), and KHCO₃ (4.748 mmol, 475 mg). Triethoxyphenylsilane (4.748 mmol, 1.141 g) and 1,4-dioxane (24 mL) were added. The reaction mixture was first stirred at room temperature for 10 min and then heated to 110 $^{\circ}$ C for 8 hours with vigorous stirring. After cooling down the reaction vessel, the second batch of the triethoxyphenylsilane (4.748 mmol, 1.141 g) and AgF (7.122 mmol, 903 mg) were added, and the mixture was then heated to 110 $^{\circ}$ C for another 10 hours with vigorous stirring. Upon completion, the solvent was removed under reduced pressure. To the residue was added KOAc (2.374 mmol, 233 mg), EtOH (24 mL, the water content of the solvent was 0.01wt %) and epoxide 2a (7.122 mmol, 627 mg). After inertion (vacuum/nitrogen), the reaction mixture was stirred at 90 $^{\circ}$ C for 35 h. Upon completion, the solvent was removed under reduced pressure. The residue was purified by column chromatography using hexane/EtOAc(50/1) as the eluent, 3m was obtained as a colorless oil (470 mg, 64%).


Ehyl 2-(5-isobutylbiphenyl-2-yl)propanoate (3m) ¹H NMR (500 MHz, CDCl₃) δ 7.47 – 7.40 (m, 2H), 7.36 (m, 4H), 7.15 (d, J = 8.0 Hz, 1H), 7.04 (s, 1H), 4.17 – 4.05 (m, 2H), 3.87 (q, J = 7.0 Hz, 1H), 2.49 (d, J = 7.0 Hz, 2H), 1.94 – 1.86 (m, 1H), 1.37 (d, J = 7.0 Hz, 3H), 1.20 (t, J = 7.0 Hz, 3H), 0.94 (d, J = 6.5 Hz, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 175.21,


141.65, 141.51, 140.05, 136.04, 130.96, 129.59, 128.68, 128.16, 127.04, 126.62, 60.63, 45.12, 41.02, 30.23, 22.57, 22.55, 19.39, 14.20. HRMS (ESI-TOF) Calcd for $C_{21}H_{27}O_2$ [M+H]⁺: 311.2006, found: 311.2006.


References


- (1) He, J.; Li, S.-H.; Deng, Y.-Q.; Fu, H.-Y.; Laforteza, B. N.; Spangler, J. E.; Homs, A.; Yu, J.-Q. *Science* **2014**, *343*, 1216.
- (2) Zhu, R.-Y.; He, J.; Wang, X.-C.; Yu, J.-Q. J. Am. Chem. Soc. 2014, 136, 13194.
- (3) He, J.; Takise, R.; Fu, H.-Y.; Yu, J.-Q. J. Am. Chem. Soc. 2015, 137, 4618.
- (4) Wasa, M.; Chan, K. S. L.; Zhang. X.-G.; He, J.; Miura, M.; Yu, J.-Q. *J. Am. Chem. Soc.* **2012**, *134*, 18570.
- (5) Ye, S.-Q.; Yang, W.-B.; Coon, T.; Fanning, D.; Neubert, T.; Stamos, D.; Yu, J.-Q. *Chemistry- A European Journal* **2016**, 22, 4748.
- (6) Fu, H.-Y.; Shen, P.-X.; He, J.; Zhang, F.-L.; Li, S.-H.; Wang, P.; Liu, T.; Yu, J.-Q. *Angew. Chem. Int. Ed.* **2017**, *56*, 1873.
- (7) McCullough, K. J.; MacTavish, J.; Proctor, G. R.; Redpath, J. J. Chem. Soc., Perkin Trans. 1996, 1, 2353.
- (8) Concell on, J. M.; Bardales, E. Org. Lett. 2002, 4, 189.


¹H and ¹³C NMR Spectra



































































































































































































































60 50

30

20

10

90 80 70

210 200 190 180 170 160 150 140 130 120 110 100 f1 (ppm)

